Tear cytokine profiles in dysfunctional tear syndrome.

PURPOSE To compare tear cytokine and chemokine concentrations in asymptomatic control and Dysfunctional Tear syndrome (DTS) patients and determine the correlations between tear inflammatory mediators and clinical severity. DESIGN Prospective observational cohort study. METHODS Concentrations of epidermal growth factor (EGF), interleukin (IL)-1 alpha (1alpha), 1 beta (1beta), 6, 10, 12, and 13, interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), and chemokines: IL-8 (CXC); macrophage inflammatory protein-1 alpha (MIP-1alpha) (CCL3); and regulated upon activation, normal T-cell expressed and secreted (RANTES CCL5) were measured by a multiplex immunobead assay in an asymptomatic control group and DTS patients with and without meibomian gland disease (MGD). Spearman correlations between tear cytokines and severity of irritation symptoms and ocular surface signs were calculated. RESULTS Tear concentrations of IL-6, IL-8 and TNF-alpha were significantly higher in DTS with and without MGD and EGF was significantly reduced in the DTS without MGD group compared with the control group. MIP-1alpha was greater in entire DTS and DTS without MGD groups than the control group and RANTES was greater in DTS with MGD than the control and DTS without MGD groups. IL-12 was significantly higher in the DTS with MGD than the DTS without MGD subgroup. Significant correlations were observed between IL-6 and irritation symptoms and between a number of cytokines and chemokines and clinical parameters. CONCLUSIONS As predicted, patients with DTS have higher levels of inflammatory mediators in their tears that show correlation with clinical disease parameters. Furthermore, different tear cytokine/chemokine profiles were observed in DTS patients with and without MGD groups.

[1]  De-Quan Li,et al.  Epithelial-immune cell interaction in dry eye. , 2008, Cornea.

[2]  S. Pflugfelder.  Antiinflammatory therapy for dry eye. , 2004, American journal of ophthalmology.

[3]  B. Reis,et al.  Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease1 , 2000 .

[4]  J. Chodosh,et al.  A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. , 2004, American journal of ophthalmology.

[5]  S. Papson,et al.  “Model” , 1981 .

[6]  Gerd Geerling,et al.  Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[7]  I. Gipson,et al.  Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. , 2000, Archives of ophthalmology.

[8]  H. Zhan,et al.  Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures , 2006, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[9]  Lee Stern,et al.  Dysfunctional Tear Syndrome: A Delphi Approach to Treatment Recommendations , 2006, Cornea.

[10]  Christophe Baudouin,et al.  Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[11]  S. Pflugfelder,et al.  Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. , 1999, Current eye research.

[12]  S. Barabino,et al.  Distribution of Conjunctival HLA-DR Expression and the Pathogenesis of Damage in Early Dry Eyes , 2005, Cornea.

[13]  De-Quan Li,et al.  Stress-activated protein kinase signaling pathways in dry eye and ocular surface disease. , 2005, The ocular surface.

[14]  Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome. , 1996, Annals of the rheumatic diseases.

[15]  L. Sobrin,et al.  Tear fluid gelatinase B activity correlates with IL-1alpha concentration and fluorescein clearance in ocular rosacea. , 1999, Investigative ophthalmology & visual science.

[16]  De-Quan Li,et al.  Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-gamma. , 2007, Investigative ophthalmology & visual science.

[17]  P. Gastaud,et al.  Immunopathological findings in conjunctival cells using immunofluorescence staining of impression cytology specimens. , 1992, The British journal of ophthalmology.

[18]  S. Pflugfelder,et al.  Alterations of ocular surface gene expression in Sjögren's syndrome. , 1998, Advances in experimental medicine and biology.

[19]  N. McNamara,et al.  Antibody array characterization of inflammatory mediators in allergic and normal tears in the open and closed eye environments. , 2007, Experimental eye research.

[20]  Jian-ping Gao,et al.  Desiccating Stress Induces T Cell-Mediated Sjögren’s Syndrome-Like Lacrimal Keratoconjunctivitis1 , 2006, The Journal of Immunology.

[21]  R. Dana,et al.  Chemokine receptor CCR5 expression in conjunctival epithelium of patients with dry eye syndrome. , 2006, Archives of ophthalmology.

[22]  S. Pflugfelder.  PERSPECTIVE Antiinflammatory Therapy for Dry Eye , 2004 .

[23]  S. Pflugfelder,et al.  Sjögren's syndrome: cytokine and Epstein-Barr viral gene expression within the conjunctival epithelium. , 1994, Investigative ophthalmology & visual science.

[24]  C. Baudouin,et al.  Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. , 2001, Investigative ophthalmology & visual science.

[25]  R. Dana,et al.  Chemokine Receptor CCR 5 Expression in Conjunctival Epithelium of Patients With Dry Eye Syndrome , 2006 .

[26]  D. Thompson,et al.  Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. , 2002, Investigative ophthalmology & visual science.

[27]  N. Mosaffa,et al.  Suppression of interleukin-6 by minocycline in a rat model of neuropathic pain. , 2006, European journal of pharmacology.

[28]  C. Creuzot-Garcher,et al.  CCR 4 and CCR 5 expression in conjunctival specimens as differential markers of T(H)1/ T(H)2 in ocular surface disorders. , 2005, The Journal of allergy and clinical immunology.

[29]  M. Korostyński,et al.  Interleukin-1alpha has antiallodynic and antihyperalgesic activities in a rat neuropathic pain model , 2008, PAIN.

[30]  Christophe Baudouin,et al.  The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[31]  F. K. Manuel,et al.  The incidence and risk factors for developing dry eye after myopic LASIK. , 2006, American journal of ophthalmology.